Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
January 5, 1999
A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity
D Cussac, M Vidal, C Leprince, et al.
Cell Transplantation
|
April 25, 2012
Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats
C Alfarano, C Roubeix, R Chaaya, et al.
Brain Research
|
November 22, 2001
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra
A Newman-Tancredi, D Cussac, M Brocco, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 17, 2003
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways
M J Millan, A Gobert, F Lejeune, et al.
The Journal of Biological Chemistry
|
March 28, 1998
Differential interactions of the growth factor receptor-bound protein 2 N-SH3 domain with son of sevenless and dynamin. Potential role in the Ras-dependent signaling pathway
M Vidal, J L Montiel, D Cussac, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 28, 2000
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
M J Millan, A Gobert, A Newman-Tancredi, et al.
Cell Transplantation
|
August 20, 2010
Evaluation of alginate microspheres for mesenchymal stem cell engraftment on solid organ
E Trouche, S Girod Fullana, C Mias, et al.
The European Journal of Neuroscience
|
April 13, 2000
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram
M J Millan, A Gobert, J M Rivet, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol
M J Millan, A Gobert, A Newman-Tancredi, et al.
Neuropharmacology
|
March 19, 2013
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety
A L Auclair, J C Martel, M B Assié, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
January 5, 1999
A Sos-derived peptidimer blocks the Ras signaling pathway by binding both Grb2 SH3 domains and displays antiproliferative activity
D Cussac, M Vidal, C Leprince, et al.
Cell Transplantation
|
April 25, 2012
Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats
C Alfarano, C Roubeix, R Chaaya, et al.
Brain Research
|
November 22, 2001
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra
A Newman-Tancredi, D Cussac, M Brocco, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
May 17, 2003
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways
M J Millan, A Gobert, F Lejeune, et al.
The Journal of Biological Chemistry
|
March 28, 1998
Differential interactions of the growth factor receptor-bound protein 2 N-SH3 domain with son of sevenless and dynamin. Potential role in the Ras-dependent signaling pathway
M Vidal, J L Montiel, D Cussac, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 28, 2000
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626
M J Millan, A Gobert, A Newman-Tancredi, et al.
Cell Transplantation
|
August 20, 2010
Evaluation of alginate microspheres for mesenchymal stem cell engraftment on solid organ
E Trouche, S Girod Fullana, C Mias, et al.
The European Journal of Neuroscience
|
April 13, 2000
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram
M J Millan, A Gobert, J M Rivet, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 11, 1998
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol
M J Millan, A Gobert, A Newman-Tancredi, et al.
Neuropharmacology
|
March 19, 2013
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety
A L Auclair, J C Martel, M B Assié, et al.
Page
of 5